Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oric Pharmaceuticals ( (ORIC) ) has shared an update.
On August 12, 2025, ORIC Pharmaceuticals announced a strategic pipeline prioritization to focus on advancing its lead clinical programs, ORIC-944 and ORIC-114, resulting in a 20% workforce reduction and a one-time cost of $1.9 million. This decision is part of a revised operating plan aimed at extending the company’s cash runway into the second half of 2028, supported by recent financing activities that raised $244 million. The company reported promising clinical data for ORIC-944 in prostate cancer and continued progress in trials for enozertinib in lung cancer, positioning itself for potential registrational trials in 2026.
The most recent analyst rating on (ORIC) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.
Spark’s Take on ORIC Stock
According to Spark, TipRanks’ AI Analyst, ORIC is a Neutral.
Oric Pharmaceuticals’ overall score reflects the significant risks associated with its current financial performance, characterized by ongoing losses and no revenue generation. Despite a strong balance sheet with substantial cash reserves, the company’s stock is under pressure due to bearish technical indicators and uncertain valuation metrics. The expansion of the equity incentive plan is a strategic positive but does not offset the immediate financial challenges.
To see Spark’s full report on ORIC stock, click here.
More about Oric Pharmaceuticals
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing treatments that address mechanisms of therapeutic resistance in cancer. Their lead product candidates include ORIC-944, an allosteric inhibitor for prostate cancer, and enozertinib (formerly ORIC-114), a brain penetrant inhibitor targeting specific genetic mutations in various cancers. The company operates out of South San Francisco and San Diego, California.
Average Trading Volume: 1,374,438
Technical Sentiment Signal: Buy
Current Market Cap: $784.1M
For detailed information about ORIC stock, go to TipRanks’ Stock Analysis page.